Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | F9 | P00740 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14106992 | 0.86 | TSHR (0.48) | PTGS2TSHRPTPN1LOXL2L3MBTL1 | |
| SCHEMBL4851404 | 0.73 | PTGS2 (0.42) | PTGS2PTPN1LOXL2TDP1 | |
| SCHEMBL14035702 | 0.72 | LOXL2 (0.39) | PTGS2PTPN1LOXL2TDP1 | |
| SCHEMBL716717 | 0.70 | GPR3 (0.46) | PTGS2PTPN1LOXL2 | |
| SCHEMBL1066576 | 0.69 | TSHR (0.67) | TSHRLOXL2TDP1L3MBTL1NAAA | |
| SCHEMBL4850613 | 0.69 | HRH1 (0.55) | — | |
| SCHEMBL23525356 | 0.69 | TSHR (0.38) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL13352406 | 0.69 | CNR2 (0.45) | PTGS2PTPN1LOXL2TDP1L3MBTL1 | |
| SCHEMBL11925834 | 0.68 | TSHR (0.44) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL28521552 | 0.68 | CNR2 (0.50) | PTGS2PTPN1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393865-B2 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| WO-2006019497-A2 | SLEEP-INDUCING COMPOUNDS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014797-A1 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014797-A1 | Sleep inducing compounds and methods relating thereto | CHRM1, CNR1, HRH3 | PTGS2 668/4885TSHR 265/4885PTPN1 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.